Financial Performance - As of March 31, 2025, Cabaletta Bio, Inc. reported total assets of $165,141,000, a decrease of 10.8% from $185,046,000 on December 31, 2024[15]. - The company incurred a net loss of $35,943,000 for the three months ended March 31, 2025, compared to a net loss of $25,047,000 for the same period in 2024, representing a 43.5% increase in losses year-over-year[18]. - The net loss per share for the three months ended March 31, 2025, was $0.71, compared to $0.51 for the same period in 2024[18]. - The accumulated deficit as of March 31, 2025, reached $385,044,000, an increase from $349,101,000 at the end of 2024[15]. - The total stock-based compensation for the three months ended March 31, 2025, was $5.16 million, compared to $3.79 million for the same period in 2024, reflecting a 36% increase[91]. - The net loss for Q1 2025 was reported at $35,943,000, compared to a net loss of $25,047,000 in Q1 2024, indicating increased operational expenditures[71]. - For the three months ended March 31, 2025, total operating expenses increased to $37.1 million from $28.0 million in the same period of 2024, representing a change of $9.1 million[144]. - Cash used in operating activities was $30.8 million for Q1 2025, compared to $24.0 million in Q1 2024, indicating an increase of $6.8 million[161]. - As of March 31, 2025, the company had $131.8 million in cash and cash equivalents, which is expected to fund operations into the first half of 2026[149]. Research and Development - Research and development expenses increased to $29,018,000 for the three months ended March 31, 2025, up 32.3% from $21,954,000 in the prior year[18]. - Research and development expenses for Q1 2025 totaled $28,973,000, a significant increase from $18,000,000 in Q1 2024, reflecting a rise in personnel and clinical trial costs[71]. - Research and development expenses rose to $29.0 million in Q1 2025, up from $22.0 million in Q1 2024, marking an increase of $7.1 million[145]. - The company anticipates continued increases in research and development and general administrative expenses, with a need for additional funding to support operations[153]. - The company plans to raise additional capital through equity offerings, debt financings, and strategic alliances to fund its operations[32]. - The company expects to incur additional losses in the future as it continues its research and development efforts and will need to raise additional capital[32]. Clinical Trials and Product Development - The FDA granted clearance for the rese-cel IND application for systemic lupus erythematosus (SLE) treatment, affecting an estimated 320,000 patients in the U.S. and 150,000 in Europe, with approximately 40% of SLE patients experiencing lupus nephritis (LN)[103]. - The RESET-SLE Phase 1/2 clinical trial is designed to treat 12 patients, with a single weight-based dose of 1.0 x 10^6 cells/kg, and is open for enrollment across multiple sites in the U.S. and one in the EU[103]. - The FDA granted Fast Track Designation for rese-cel for SLE and LN, and the RESET-Myositis trial is actively enrolling patients with three myositis subtypes, affecting approximately 70,000 patients in the U.S. and 85,000 in Europe[104]. - The RESET-SSc trial for systemic sclerosis (SSc) is designed to treat 12 patients, with SSc affecting approximately 90,000 patients in the U.S. and 60,000 in Europe[105]. - The RESET-MG trial for generalized myasthenia gravis (gMG) is open for enrollment, targeting approximately 55,000 patients in the U.S. and 100,000 in Europe[107]. - As of May 9, 2025, 44 patients are enrolled and 23 patients have been dosed across multiple Phase 1/2 disease cohorts in the RESET clinical development program[118]. - The company is collaborating with Cellares Corp. to evaluate an automated manufacturing platform, with successful integration of the Cell Shuttle™ into the manufacturing strategy for rese-cel[120]. - The company plans to implement two registrational cohorts in the RESET-Myositis trial, each evaluating approximately 15 patients, with a focus on achieving a broad label for myositis treatment[116]. Financial Position and Liabilities - Total current liabilities rose to $33,989,000 as of March 31, 2025, compared to $27,086,000 on December 31, 2024, indicating a 25.4% increase[15]. - The company has an accumulated deficit of $385.0 million as of March 31, 2025, indicating ongoing financial challenges[152]. - Future lease payments under non-cancelable leases as of March 31, 2025, total $25,444,000 for finance leases and $5,939,000 for operating leases[79]. - The company has no off-balance sheet risks, such as foreign exchange contracts or other hedging arrangements, ensuring a straightforward financial position[37]. - The company has not recorded any income tax benefits for the three months ended March 31, 2025, due to the likelihood of not recognizing deferred tax benefits[95]. Risks and Challenges - The company has not yet established sales and marketing capabilities, which will be crucial upon obtaining regulatory approval to gain market acceptance[192]. - The regulatory approval process for the company's novel product candidates is complex and may take longer than expected, with potential delays in commercialization[190]. - Patients receiving T cell-based immunotherapies may experience serious adverse events, which could negatively affect the clinical development and commercial potential of the company's product candidates[193]. - The company faces inherent product liability risks during clinical testing, which could lead to substantial liabilities and limit commercialization efforts[209]. - The company currently does not hold product liability insurance for commercialization, which could inhibit the ability to market products if claims arise[210]. - Adverse events from CAR T cell therapies have resulted in patient deaths, indicating significant risks associated with current and future product candidates[213]. - The company is early in its development efforts and may face significant delays in clinical trials if suitable doses are not identified[188]. - The company must navigate variability in T cell quality and quantity, which could affect the reliability of manufacturing its product candidates[186]. Agreements and Collaborations - The Company is committed to pay up to $2,250,000 under the CARTA Services Agreement for cell processing manufacturing through December 31, 2025[54]. - The IASO Agreement includes an upfront payment of $2.5 million and potential total consideration of up to $162 million based on milestone achievements[123]. - The Company entered into a License and Supply Agreement with Oxford Biomedica, which includes an upfront fee and potential regulatory and sales milestone payments in the low tens of millions[124]. - The Company has entered into a Development and Manufacturing Services Agreement with Lonza for a term of 12 months, with the ability to extend, focusing on the CAR-T cell therapy product rese-cel[62]. - An Option and License Agreement with Autolus was established, requiring an upfront license fee of $1,200, with potential regulatory milestones of up to $12,000 for each licensed target and sales milestones totaling up to $15,000[59].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Delaware 001-39103 82-1685768 (Commission File Number) (IRS Employer 2929 Arch Street Suite 600 Philadelphia, Pennsylvania 19104 (Address of Principal Executive ...

– SLE and LN registrational discussions with FDA anticipated in 3Q25; systemic sclerosis registrational discussions with FDA anticipated in 4Q25 – – New clinical data on rese-cel in myositis, SLE / LN and systemic sclerosis to be presented in three oral sessions at the EULAR 2025 Congress in June – – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – As of March 31, 2025, the Company had cash and cash equivalents of $131.8 million, per our Form 10-Q being filed ...

Clinical Trials and Approvals - The FDA granted clearance for the IND application of rese-cel for treating systemic lupus erythematosus (SLE) and lupus nephritis, affecting approximately 320,000 patients in the U.S. and 150,000 in Europe[16]. - The RESET-SLE Phase 1/2 clinical trial is designed to treat six SLE patients with active lupus nephritis and six patients with active SLE without renal involvement, using a single weight-based dose of 1.0 x 10^6 cells/kg[16]. - The FDA also granted Fast Track Designation for rese-cel to improve disease activity in patients with SLE and lupus nephritis[16]. - The RESET-Myositis Phase 1/2 clinical trial is actively enrolling patients with idiopathic inflammatory myopathies, affecting approximately 70,000 patients in the U.S. and 85,000 in Europe[17]. - The RESET-SSc Phase 1/2 clinical trial for systemic sclerosis is designed to treat six patients with severe skin manifestations and six with severe organ involvement, with SSc affecting approximately 90,000 patients in the U.S. and 60,000 in Europe[18][19]. - The RESET-MG Phase 1/2 clinical trial for generalized myasthenia gravis is designed to treat six patients with AChR-positive and six with AChR-negative gMG, affecting approximately 55,000 patients in the U.S. and 100,000 in Europe[20]. - The RESET-MS Phase 1/2 trial for multiple sclerosis has been cleared by the FDA, targeting approximately 750,000 patients in the U.S. and 550,000 in Europe[25]. - Cabaletta has received five IND applications cleared within the routine 30-day period for RESET Phase 1/2 clinical trials in SLE, myositis, SSc, gMG, and MS, in addition to the RESET-PV trial[37]. - The company aims to achieve compelling clinical responses with its lead product candidate, rese-cel, which has shown complete clinical responses in five out of five patients with moderate to severe, refractory SLE[38]. - Rese-cel is designed to transiently deplete all B cells after a single infusion, potentially resetting the immune system and providing meaningful clinical responses off immunosuppressive therapies[48]. - The RESET Phase 1/2 clinical trials are structured with independent cohorts of six patients each, allowing for parallel enrollment and dosing, with a weight-based cell dose of 1.0 x 10^6 cells/kg[39]. - The company is advancing RESET™ Phase 1/2 clinical trials in systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc), generalized myasthenia gravis (gMG), pemphigus vulgaris (PV), and multiple sclerosis (MS) with specific cohorts expected to comprise 6 patients each[61]. Market and Patient Impact - Approximately 320,000 patients in the U.S. and 150,000 patients in Europe are estimated to be affected by SLE, with lupus nephritis impacting about 40% of SLE patients[54]. - Myositis affects approximately 70,000 patients in the U.S. and 85,000 patients in Europe, with many patients remaining refractory to existing medications[56]. - Systemic sclerosis (SSc) affects around 90,000 patients in the U.S. and 60,000 patients in Europe, with an average survival of approximately 12 years following initial diagnosis[57]. - Generalized myasthenia gravis (gMG) affects about 55,000 patients in the U.S. and 100,000 patients in Europe, with standard therapies requiring chronic administration[58]. - Pemphigus vulgaris (PV) affects approximately 15,000 patients in the U.S. and 20,000 patients in Europe, with a reported mortality risk 2- to 3-fold higher than the general population[59]. - DSG3-CAART is designed to specifically target autoreactive B cells in mucosal pemphigus vulgaris, with approximately 15,000 prevalent patients in the U.S., of which 25% have mucosal PV[63]. Manufacturing and Collaboration - The company is collaborating with Cellares Corp. to evaluate an automated manufacturing platform for rese-cel, aiming to improve scalability and reduce costs[30]. - The company plans to secure commercial manufacturing capabilities through partnerships and the establishment of its own facilities, leveraging expertise from previous cell therapy organizations[29]. - The legacy CAART platform has produced two clinical-stage cell therapy programs in mPV and MuSK MG, with successful management of clinical trials across over a dozen sites in the U.S. over the past five years[35]. - The company has expanded its CDMO agreements with Lonza to supply rese-cel clinical product under current Good Manufacturing Practices by the second half of 2025[70]. - The company aims to achieve full manufacturing independence through expanding CDMO relationships and establishing its own manufacturing facilities[74]. Regulatory Environment - The company’s products are classified as biologics and will require compliance with cGMP regulations, clinical trials, and submission of a Biologics License Application (BLA) for marketing authorization[97]. - The FDA requires extensive preclinical and clinical testing before a BLA can be submitted, including laboratory evaluations and animal studies[101]. - Clinical trials are conducted in three phases, with Phase 3 trials typically requiring two adequate and well-controlled studies for BLA approval[107]. - The BLA submission must include proof of safety, purity, potency, and efficacy, supported by extensive testing data[110]. - The company must comply with federal, state, and local regulations, which require substantial time and financial resources for obtaining regulatory approvals[99]. - Failure to comply with applicable regulations may result in significant delays or sanctions, including refusal of approval or product recalls[100]. - The FDA's goal is to review Biologics License Applications (BLAs) within 10 months for standard review and 6 months for priority review[112]. - The FDA may issue a Complete Response Letter if the BLA has deficiencies, which could require additional clinical data or trials[115]. - Orphan drug designation can be granted for products intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S.[117]. - Products with orphan drug designation receive exclusivity for 7 years post-approval, preventing other applications for the same indication[119]. - The FDA's Fast Track program allows for expedited review of drugs that address unmet medical needs for serious conditions[120]. - Priority review can shorten the review timeframe to 6 months if the product shows significant improvement in safety and effectiveness[122]. - Accelerated approval may be granted for drugs that provide meaningful advantages over existing therapies, based on surrogate endpoints[123]. - Breakthrough therapy designation expedites development for products showing substantial improvement over existing therapies[124]. - The FDA's RMAT program facilitates the development of regenerative medicine therapies intended for serious conditions[125]. - Post-marketing requirements include ongoing monitoring and reporting of adverse experiences with the product[127]. - The company relies on third parties for the production of clinical and commercial quantities of products in accordance with cGMP regulations, which require extensive quality control and assurance measures[129]. - The FDA may impose post-approval testing and surveillance, which can lead to restrictions on product distribution or use if new safety or effectiveness data emerges[130]. - The company is subject to various regulatory authorities beyond the FDA, including CMS and state agencies, which impose compliance requirements that can affect sales and marketing activities[131]. - Non-compliance with regulatory requirements can result in severe penalties, including criminal prosecution, fines, and product recalls, which could materially impact the company's operations[133]. Intellectual Property and Licensing - The company has in-licensed one patent family for rese-cel, which includes a pending U.S. patent application expected to expire in 2040[84]. - As of March 1, 2025, the company holds seven granted U.S. patents and 50 pending foreign patent applications[83]. - The company entered into a license agreement with the University of Pennsylvania and the Children's Hospital of Philadelphia, granting a non-exclusive, worldwide research license and an exclusive, royalty-bearing license effective from October 2018[93]. - The license agreement will expire upon the termination of the last valid claim in Penn's intellectual property, with the option for the company to terminate for convenience with 60 days' notice[94]. - A Master Translational Research Services Agreement was established in October 2018, with services related to research and development, which will expire upon completion of the services or by October 19, 2021[95]. - A second Master Translational Research Services Agreement was entered into in February 2023, which will expire on February 9, 2026, or upon completion of the services[96]. Financial and Market Challenges - The company faces competition from larger pharmaceutical and biotechnology companies with greater financial resources and expertise[78]. - Coverage and reimbursement for products depend on third-party payors, which are increasingly reducing reimbursements and may require extensive pharmacoeconomic studies[140]. - The pricing of pharmaceutical products outside the U.S. is often subject to governmental control, leading to significantly lower prices compared to the U.S. market[144]. - The company may face civil penalties under the federal civil False Claims Act for presenting false claims to federal programs, with penalties including three times the actual damages sustained by the government[147]. - The company is subject to data privacy and security regulations, including HIPAA, which imposes significant civil and criminal penalties for violations[149]. - The Affordable Care Act (ACA) has increased the company's rebate liability by raising the minimum basic Medicaid rebate on average manufacturer price for most branded prescription drugs[159]. - The Inflation Reduction Act of 2022 reduces the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 effective in 2025, impacting the company's financial liability[161]. - The company must comply with state laws requiring registration of manufacturers and distributors, which may include new technology for tracking products in the distribution chain[154]. - The company is subject to scrutiny under federal and state consumer protection laws, which could affect its marketing and sales practices[155]. - Legislative changes may impose new pricing transparency requirements and affect the company's pricing strategies for pharmaceutical products[160]. - The company faces potential reductions in Medicare payments due to the Budget Control Act of 2011, which could adversely affect its profitability[163]. - The company must navigate complex compliance efforts due to varying state laws governing the pharmaceutical industry, which may differ significantly from federal regulations[151]. - The Foreign Corrupt Practices Act requires the company to maintain accurate records and internal controls for international operations, impacting its global business practices[166]. Workforce and Corporate Culture - As of December 31, 2024, the company had 164 employees, with 135 engaged in research and development activities[177]. - The company has not yet completed any clinical trials, and revenue generation is not expected for many years[186]. - The company is focused on advancing its product candidates through clinical development and obtaining regulatory approvals[186]. - The company has a good relationship with its employees, with no labor union representation[177]. - The company’s future success depends on attracting and retaining key personnel and maintaining a strong corporate culture[178]. Development Risks and Challenges - The company is developing CAR T and CAAR T product candidates for autoimmune diseases, facing challenges in manufacturing, sourcing materials, and ensuring quality of T cells[191]. - The regulatory approval process for the company's novel product candidates is complex and may take longer than for existing therapies, with higher development risks and costs[195]. - The company has observed serious adverse events in clinical trials, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which could impact the commercial potential of its product candidates[197]. - The company is implementing preconditioning regimens in clinical trials, which may increase the risk of adverse effects and complicate efficacy assessments[203]. - The company may need to rely on subjective measurements of treatment activity due to potential issues with standard clinical assays, which could delay clinical development[205]. - The company is exploring various preconditioning regimens, including antibody-reducing therapies, which may have serious adverse events associated with them[206]. - The company is early in the clinical development process and cannot predict long-term effects from its product candidates[192]. - The company may experience delays in finding suitable doses for pivotal trials, impacting clinical development timelines[193]. - The company must educate medical personnel on the potential side effects of its product candidates, which may not be recognized in routine care[202]. - The company faces potential regulatory changes due to public perception and ethical concerns, which could limit its ability to commercialize product candidates[196]. - The company is highly dependent on the success of its initial product candidates targeting autoimmune diseases involving B cells, requiring significant additional preclinical and clinical development before seeking regulatory approval[209]. - The initial clinical results observed may not predict outcomes for subsequent cohorts or future trials, indicating potential complications in trial design and execution[210]. - The company has never successfully completed any clinical trials, which raises concerns about its ability to obtain regulatory approvals and commercialize products[213]. - There is a risk that adverse effects from preconditioning regimens could delay patient enrollment in clinical trials and impact regulatory approval processes[208]. - The company may face significant challenges in obtaining marketing approval for its product candidates, which is a lengthy and risky process[209]. - If required to conduct additional clinical trials or testing beyond current plans, the company may incur substantial liabilities from product liability lawsuits[214]. - Treatment-related side effects observed in clinical trials could harm the company's development plans and business prospects[211]. - The company may not be able to file INDs or CTAs for future product candidates on expected timelines, affecting clinical trial commencement[213]. - The occurrence of safety concerns or modestly positive trial results could limit commercialization of the company's product candidates[214]. - Regulatory authorities may change their position on trial designs or clinical endpoints, potentially requiring additional trials or stricter approval conditions[213].

Financial Position - As of December 31, 2024, Cabaletta Bio reported unaudited cash and cash equivalents of $164 million, expected to fund operations into the first half of 2026[4]. Clinical Development - 21 patients have been enrolled across 44 actively recruiting clinical sites in the RESET clinical development program as of December 31, 2024[11]. - The first patient has been enrolled in the RESET-PV trial, evaluating rese-cel without preconditioning in patients with pemphigus vulgaris[11]. - The first juvenile myositis clinical site in the RESET-Myositis trial is now open and actively recruiting[16]. Clinical Outcomes - In the first 10 patients dosed with rese-cel, 90% experienced no cytokine release syndrome (CRS) or grade 1 CRS, and 90% experienced no immune effector cell-associated neurotoxicity syndrome (ICANS)[11]. Regulatory Affairs - Cabaletta plans to meet with the FDA regarding registrational trial designs for rese-cel in the first half of 2025[12]. - The FDA has granted Fast Track Designation to rese-cel for the treatment of relapsing and progressive forms of multiple sclerosis (MS)[16]. Manufacturing and Supply Chain - Cabaletta has expanded its CDMO agreement with Lonza to supply rese-cel clinical product under current Good Manufacturing Practices by the second half of 2025[16]. - Cabaletta is advancing a whole blood manufacturing program as a potential replacement for apheresis and seeks to align with the FDA on this strategy[17]. Future Plans - The company aims to present new and updated clinical and translational data on rese-cel throughout 2025[13].

– Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical- stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. "We are lookin ...

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [3] - The company will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 11:50 a.m. ET in Boston, MA [1] - A live webcast of the presentation will be available on the company's website, with replays accessible for 30 days [2] Company Overview - Cabaletta Bio is dedicated to advancing engineered T cell therapies that may provide deep and durable, potentially curative treatments for a variety of autoimmune diseases [3] - The company's lead strategy, CARTA, focuses on the development of rese-cel, a fully human CD19-CAR T cell investigational therapy containing 4-1BB [3] - Rese-cel is currently being evaluated in the RESET™ clinical development program, which spans multiple therapeutic areas including rheumatology, neurology, and dermatology [3]

Core Insights - Cabaletta Bio, Inc. has presented new clinical data indicating the efficacy of resecabtagene autoleucel (rese-cel) in treating autoimmune diseases, with significant improvements observed in patients with systemic lupus erythematosus (SLE), lupus nephritis (LN), and dermatomyositis [1][2][9] - The company aims to align with the FDA on registrational trial designs in the first half of 2025, leveraging the expanding clinical experience and enrollment pace across its RESET clinical development program [2][10] Clinical Data Summary - As of January 8, 2025, 10 patients have been dosed with rese-cel, showing promising results such as DORIS remission in SLE and complete renal response in LN, with patients off immunosuppressants and tapering steroids [3][9] - In the RESET-Myositis trial, the first adult dermatomyositis patient maintained a major total improvement score (TIS) at 3 months post-infusion, indicating potential for drug-free remission [3][9] Safety Profile - The safety profile of rese-cel appears favorable, with 90% of patients experiencing either no cytokine release syndrome (CRS) or Grade 1 CRS, and 90% experiencing no immune effector cell-associated neurotoxicity syndrome [4][9] - Deep B cell depletion was observed in all patients post-infusion, with a transitional naïve B cell phenotype upon repopulation, suggesting effective immune system resetting [4][9] Clinical Development Program - The RESET program includes six Phase 1/2 clinical trials targeting various autoimmune diseases, with a focus on rheumatology, neurology, and dermatology [2][6][7] - The company is actively recruiting at 50 clinical sites in the U.S. and Europe, with 26 patients enrolled as of February 13, 2025 [4][9]

Core Insights - Cabaletta Bio, Inc. announced promising clinical data for resecabtagene autoleucel (rese-cel), showing significant clinical responses in patients with autoimmune diseases, including systemic lupus erythematosus (SLE), lupus nephritis (LN), and dermatomyositis, with patients off all immunosuppressants and steroids [1][2][9] Clinical Data Summary - As of January 8, 2025, 10 patients were dosed with rese-cel across the RESET clinical trials, with notable outcomes including DORIS remission in 3 out of 4 SLE patients and a complete renal response in the first LN patient [3][9] - The RESET-Myositis trial showed that the first adult dermatomyositis patient maintained a major total improvement score at 3 months post-infusion, indicating potential for drug-free remission [3][9] - In the RESET-SSc trial, the first patient demonstrated significant skin improvements and lung function enhancement after discontinuing all disease-specific therapies [9] Safety Profile - The safety profile of rese-cel appears favorable, with 90% of patients experiencing either no cytokine release syndrome (CRS) or Grade 1 CRS, and 90% experiencing no immune effector cell-associated neurotoxicity syndrome [4][9] - Deep B cell depletion was observed in all patients post-infusion, with a transitional naïve B cell phenotype upon repopulation, confirming tissue-resident B cell elimination [4][9] Clinical Development Program - Cabaletta is conducting the RESET clinical development program, which includes six Phase 1/2 trials targeting various autoimmune diseases, with an average of one patient enrolling per week since November 2024 [2][4][6] - The company plans to present the clinical data to the FDA to align on registrational trial designs in the first half of 2025 [2][10] Company Overview - Cabaletta Bio is focused on developing curative targeted cell therapies for autoimmune diseases, with rese-cel being a key investigational therapy designed to reset the immune system through deep depletion of CD19-positive B cells [6][7]

Group 1 - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [4] - The company will present updated clinical data on its investigational therapy rese-cel at two upcoming scientific meetings in February 2025 [1][2] - Rese-cel is designed to transiently and completely deplete all CD19-positive cells, potentially resetting the immune system for patients with autoimmune diseases [3] Group 2 - The RESET™ clinical development program includes multiple disease-specific trials across various therapeutic areas such as rheumatology, neurology, and dermatology [3][4] - The lead strategy of Cabaletta Bio, CARTA, aims to advance engineered T cell therapies for autoimmune diseases [4] - Presentations at the scientific meetings will cover safety, translational data, and clinical outcomes from the first 10 patients dosed with rese-cel [1][2]